Sierra Oncology Inc. (SRRA) |
|
11.02 0.35 (3.28%)
|
10-01 16:03 |
|
Open: |
10.6498 |
Pre. Close: |
10.67 |
|
High:
|
11.02 |
Low:
|
10.6498 |
|
Volume:
|
1,114 |
Market Cap:
|
115M |
|
|
|
|
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.314 - 11.369 |
11.369 - 11.424 |
|
Low:
|
10.424 - 10.491 |
10.491 - 10.556 |
|
Close:
|
10.547 - 10.652 |
10.652 - 10.756 |
|
Technical analysis |
as of: 2020-10-01 3:39:31 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 15.02 One year: 16.73 |
| Support: |
Support1: 10.50 Support2: 8.74 |
| Resistance: |
Resistance1: 12.86 Resistance2: 14.32 |
| Pivot: |
11.17  |
| Moving Average: |
MA(5): 10.82 MA(20): 11.37
MA(100): 12.49 MA(250): 178.05 |
| MACD: |
MACD(12,26): -0.35 Signal(9): -0.29 |
| Stochastic oscillator: |
%K(14,3): 12.59 %D(3): 12.44 |
| RSI: |
RSI(14): 42.44 |
| 52-week: |
High: 880.00 Low: 8.55 Change(%): -98.3 |
| Average Vol(K): |
3-Month: 2270 10-Days: 1227 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.SRRA has closed above bottom band by 30.0%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 14 Sep 2020
Sierra to Present at September Investor Conferences - PRNewswire
Fri, 04 Sep 2020
What You Need To Know About Sierra Oncology, Inc.'s (NASDAQ:SRRA) Investor Composition - Yahoo Finance
Thu, 20 Aug 2020
Sierra Oncology Inc (SRRA) Stock: What Does the Chart Say? - InvestorsObserver
Thu, 20 Aug 2020
Chief Development Officer Barbara Klencke Just Bought 162% More Shares In Sierra Oncology, Inc. (NASDAQ:SRRA) - Simply Wall St
Tue, 28 Jul 2020
Sierra Oncology Appoints Christina Thomson as General Counsel - GlobeNewswire
Thu, 18 Jun 2020
Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
10 |
| Shares Float (M) |
3 |
|
% Held by Insiders
|
3.42 |
|
% Held by Institutions
|
57.14 |
|
Shares Short (K)
|
7 |
|
Shares Short P. Month (K)
|
4 |
Stock Financials |
|
EPS
|
-15.270 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
11.220 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-40.3 |
|
Return on Equity (ttm)
|
-116.2 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-6.500 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-48 |
|
Levered Free Cash Flow (M)
|
-32 |
Stock Valuations |
|
PE Ratio
|
-0.71 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.96 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-2.35 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
